New England Peptide, a Gardner, MA-based provider of custom peptides and antibodies to the global life sciences market, received a majority recapitalization from Ampersand Capital Partners.
The amount of the deal was not disclosed. As part of the transaction, Dr. José de Chastonay joined as Executive Chairman of New England Peptide’s Board of Directors.
The company intends to use the funds for worldwide growth initiatives, including accelerating the expansion of peptide synthesis capabilities.
Founded in 1998 by Sam and Jennifer Massoni, New England Peptide designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations worldwide.
The company specializes in custom peptide synthesis, polyclonal antibody production, stable-labeled bioanalytical peptide standards, and catalog peptide products serving a premier roster of pharmaceutical and biotechnology companies and academic/research institutions.
New England Peptide operates in a 25,000 square foot facility with laboratory space to service all customer and regulatory requirements.